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A B S T R A C T   
Cognitive impairment is a core aspect of psychotic disorders and difficult to treat. Atypical antipsychotics (AAs) 
might have differential effects on cognitive impairment, but rigid study designs and selective sampling limit the 
generalizability of existing findings. This pragmatic, semi-randomized, industry-independent study aimed to 
investigate and compare the effect of amisulpride, aripiprazole and olanzapine on cognitive performance in 
psychosis over a 12-month period controlling for diagnostic group. 
This sub study of the BeSt InTro study recruited adults with ongoing psychosis in the schizophrenia spectrum 
of disorders (ICD-10 diagnoses F20-F23, F25, F28 or F29; n = 104) from Bergen and Stavanger, Norway; and 
Innsbruck, Austria. Participants were randomized to amisulpride, aripiprazole, or olanzapine and they completed 
neuropsychological assessments at baseline, 6 weeks, 6 and 12 months. The test battery targeted working 
memory, verbal ability, and processing speed. We used Longitudinal mixed effect (LME) models to assess 
cognitive change for intention to treat (ITT) and per protocol (PP) medication groups, as well as comparing 
cognitive performance between F20 and non-F20 participants. 
The sample baseline global cognitive performance t-score was 42.20. Global performance improved signifi-
cantly to every follow-up, including for the F20 group. There were however no significant differences in 
cognitive change over time between neither ITT nor PP medication groups.   
1. Introduction 
Cognitive impairment is a core symptom dimension of schizophrenia 
(Kahn and Keefe, 2013) and also occurs in other psychotic disorders 
(Bortolato et al., 2015). Cognitive impairment in first-episode psychosis 
(FEP) is consistently related to poor social and vocational functioning, 
and is a stronger predictor of halted recovery than are baseline positive 
and negative symptoms (Santesteban-Echarri et al., 2017). This makes 
cognitive challenges an essential treatment target in psychosis. 
Although effective against positive symptoms, antipsychotic medi-
cation effects on cognitive impairment are uncertain. The advent of 
atypical antipsychotics (AA) in the 90s gave rise to optimism, with 
studies finding domain specific drug effects, e.g. olanzapine for verbal 
fluency problems (Meltzer and McGurk, 1999) and clozapine for atten-
tion (Sharma and Mockler, 1998). Early claims of differential effects 
have however failed to find more recent support in chronic schizo-
phrenia (Keefe et al., 2007a) or FEP (Malla et al., 2004) samples. 
Reasons for this discrepancy are unclear. However, early studies 
were to a large extent industry funded and recruited severely ill or 
chronic patient groups, e.g. only chronic schizophrenia patients (Bagnall 
et al., 2003), which may have affected the ecological validity of their 
findings. Although such designs demonstrate pre-marketing drug effi-
cacy, findings may not be generalizable to every-day clinical practice. 
Clinical guidelines call for antipsychotic drug treatment to be initiated e. 
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g. during acute first-episode psychosis (Barnes et al., 2019; NICE, 2014; 
Norwegian Directorate of Health, 2013), when exact diagnoses are hard 
to determine. Follow-up periods have frequently been short, e.g. two 
months (Riedel et al., 2010), while clinically, AAs are used over time. 
Recent reviews however note that early findings on atypical antipsy-
chotics effects might have been related to participants changing from 
high doses of cognition impairing first-generation antipsychotics, and 
that although atypical antipsychotics s outperform first-generation an-
tipsychotics for cognitive symptoms, effects sizes have been small 
(Désaméricq et al., 2014). One comprehensive meta-analysis concluded 
that there were no differences in effect on overall cognitive functioning 
between first- nor second-generation APs at all (Nielsen et al., 2015), 
though a more recent network meta-analysis found olanzapine to have a 
superior effect on overall score as well as most sub-domains, whereas 
haloperidol ranked below every other drug on every domain ranking 
(Baldez et al., 2021). To further complicate matters, although positive 
symptoms may rapidly abate at the initiation of APs, cognitive impair-
ment might take longer to respond (Désaméricq et al., 2014). This leaves 
a need for independent studies focusing on samples more representative 
of the wide range of patients receiving these drugs in clinical settings. 
All current APs, including AAs, are functional striatal dopamine D2 
antagonists. The current dopamine theory of schizophrenia postulates 
that positive symptoms arise by excessive mesostriatal dopamine sig-
nalling causing aberrant salience (Howes and Nour, 2016) while nega-
tive symptoms are associated with low prefrontal dopamine and D1 
receptor dysfunction (Howes and Kapur, 2009). Cognitive processes like 
attention, language processing and working memory all depend on 
dopamine-prefrontal interactions for organization and temporal plan-
ning of problem solving strategies (Barch and Ceaser, 2012). Although 
psychosocial stressors, cognitive reserve (Vance et al., 2010), brain 
structural (Jirsaraie et al., 2018) and connectivity (Giraldo-Chica et al., 
2018) factors all affect cognitive performance in psychosis, any distur-
bance to dopaminergic signalling is also likely to impair a range of 
cognitive functions. 
Despite all APs displaying functional D2 antagonism, AAs differ in 
their pharmacological profiles and might thus differentially affect brain 
function, both positively and negatively. The new line of partial D2 
agonists, of which aripiprazole is the first, may be of particular rele-
vance. Whereas amisulpride and olanzapine are strict D2 blockers 
aiming to counteract striatal hyperdopaminergia, the partial D2 agonists 
in theory also address prefrontal hypodopaminergia, thus targeting both 
aspects of the dopaminergic paradox (Howes and Kapur, 2009). In areas 
of excessive dopamine signalling the partial agonist will compete with 
endogenous dopamine for postsynaptic D2 receptors, thereby mediating 
functional D2 antagonism. In dopamine deficient prefrontal areas, a 
partial agonist may, contrary to the antagonists, increase dopamine 
signalling. For this reason, D2 partial agonists often are referred to as 
dopamine stabilizers, and might be expected to positively affect cogni-
tion. Indeed, animal models of aripiprazole have indicated improved 
prefrontal dopaminergic function (Li et al., 2004). 
The AAs under investigation also differ in extra-dopaminergic re-
ceptor affinities. Amisulpride primarily targets D2 and D3 receptors with 
minimal effect on other neurotransmitter systems. Its cognitive effects 
are not well explored but one study found it to outperform high 5HT2 
affinity AAs for sustained attention (Tyson et al., 2006). Olanzapine has 
a broad affinity profile in addition to dopaminergic antagonism, 
affecting serotonergic (5HT2) and adrenergic receptors as well as being 
a muscarinic acetylcholine (M3) and histaminergic (H1) receptor 
antagonist. H1 antagonists are known to impair psychomotor speed and 
memory scanning (Van Ruitenbeek et al., 2010), while anticholinergic 
effects may negatively affect verbal learning and visual memory (Chew 
et al., 2006). In sum, AAs might be expected to have differential positive 
and negative effects on cognitive functioning (Steen et al., 2017), with 
aripiprazole ostensibly displaying the most promising pro-cognitive re-
ceptor profile. Examining between-drug differences for cognition might 
thus yield clinically important information, as this would prevent the 
singular effects of each drug from drowning each other out at the stage 
of analysis. 
In sum, there is a need for updated knowledge on differential effects 
of AA on cognition, based on clinically representative samples followed 
up over a sufficient period of time. It would also be interesting to 
compare effects in schizophrenia vs non-schizophrenia groups given that 
the cognitive trajectory is thought to be less favourable and responsive 
in schizophrenia. The aim of this study was therefore to compare the 
effectiveness on cognition of the three AAs aripiprazole, olanzapine and 
amisulpride over a 12-month period, in a clinically representative 
sample. Study drugs were specifically selected for their differing phar-
macological and receptor affinity profiles, and based on previous effi-
cacy comparison studies (Leucht et al., 2013). This is the first direct 
head-to-head comparison of the effect of these antipsychotic drugs on 
cognition in psychotic disorders. We also aimed to compare differences 
in cognitive change between schizophrenia and other psychotic disor-
ders, in order to investigate whether there is less change in participants 
with schizophrenia. 
2. Methods 
2.1. Design and duration 
Participants were part of the Bergen-Stavanger-Innsbruck- 
Trondheim (BeSt InTro) study, a semi-randomized, rater-blinded 
multisite comparison of amisulpride, aripiprazole, and olanzapine. 
Participants for the current sub-study were recruited from Bergen and 
Stavanger in Norway and from Innsbruck in Austria. Participants were 
followed for a year, corresponding with the minimum recommended 
maintenance period of drug therapy after an acute psychotic episode. 
They completed a brief neuropsychological assessment at baseline, 6 
weeks, and 6 and 12 months. 
2.2. Study population 
The BeSt InTro inclusion criteria were age >18, a score ≥4 on either 
of the Positive And Negative Symptoms Scale (PANSS) scale (Kay et al., 
1987) items for delusions (P1), hallucinatory behaviour (P3), grandi-
osity (P5), suspiciousness/persecution (P6) or unusual thought content 
(G9), and ability to understand and speak the site native language. 
Exclusion criteria were psychoactive drug use or neurological or endo-
crine disorders likely to have caused the presented psychotic symptoms. 
Trained clinicians administered the Structured Clinical Interview for the 
DSM-IV Axis I Disorders (SCID I) (Gibbon et al., 1997) to determine 
DSM-IV diagnoses. We converted these to ICD-10 (World Health Orga-
nization, 2009) diagnoses, with schizophrenia (F20), schizotypal dis-
order (F21), delusional disorder (F22), acute psychotic disorders (F23), 
schizoaffective disorder (F25), other non-organic psychotic disorders 
(F28), and unspecified nonorganic psychosis (F29) eligible for inclusion. 
Participants gave their written informed consent for participation and 
had to be eligible for oral antipsychotic drug treatment as determined by 
their attending clinician. Inclusion in the current sub-study also required 
completion of at least one neuropsychological assessment. 
The enrolment flow is displayed in Fig. 1. Out of the 144 patients 
randomized, 104 completed baseline neuropsychological assessment. A 
further 11 had completed at least one non-baseline assessment. These 
could not be included in the baseline analyses but were included in the 
LME model development in order to strengthen the model. Inability to 
complete baseline neuropsychological testing was not quantitatively 
assessed, but a common reason was that the person was too unstable or 
unwell to be tested. 
2.3. Study medication 
Study medication consisted of oral tablets administered according to 
Summary of Product Characteristics for each drug with dosing intervals 
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as follows: Amisulpride 50–1200 mg/day; aripiprazole 5–30 mg/day; 
and olanzapine 2.5-20 mg/day. 
2.4. Open randomization 
Study drug allocation was open to participants and clinical treatment 
teams, while research assessment teams remained blinded. Study- 
independent statisticians at the University of Bergen made computer 
generated consecutively numbered drug randomization envelopes, each 
containing all three study drugs listed in random order. Each partici-
pant's attending physician would open the envelope and offer the 
topmost listed drug. If the primary allocation was unacceptable for 
example due to previous negative experiences with the study drug, the 
second listed drug was offered, while noting the reason for unselecting 
the first. This procedure was repeated if the second listed drug was also 
rejected. Initiation and dosage of the chosen medication as well as any 
subsequent changes were left to the clinician's discretion. 
Intention-to-treat (ITT) groups for analysis were based on the first 
study drug listed in participants' randomization envelope. Per protocol 
(PP) analysis groups were based on the study drug actually chosen. 
2.5. Concomitant medications 
In line with common clinical practice, we allowed use of concomitant 
medications. In line with available knowledge and treatment guidelines 
(Barnes et al., 2019; NICE, 2014; Norwegian Directorate of Health, 
2013), we strongly discouraged antipsychotic polypharmacy, while 
allowing limited periods of cross-titration during antipsychotic drug 
switches. 
2.6. Outcome measures 
The brief neurocognitive test battery was administered by trained 
staff, took 45–60 min to complete and was designed to target working 
memory, selective attention, executive functioning, verbal learning, and 
processing speed. These high-level functions rely on frontal lobe func-
tion and are likely to be affected by drug-related changes in 
dopaminergic activity. The battery consisted of Dichotic Listening, Trail 
Making A (TMA) and Trail Making B (TMB) from the Halsted-Reitan test 
set (Reitan, 1958), The Hopkins Verbal Learning Test (HVLT-R) (Bene-
dict et al., 1998), WAIS-IV letter number sequencing (Wechsler, 1997), 
and the D-KEFS FAS verbal fluency tests and Symbol Coding (Delis et al., 
2004), administered in that order. We used alternative versions of the 
HVLT-R for each follow-up, and overall chose tests less vulnerable to 
learning effects. Raw test scores were converted to t-scores by way of 
their respective norm based scoring manuals. We calculated average t- 
scores for a global cognitive measure based on all subtests as well as 
three subdomain t-scores based on scores from respective subtests: 
Working memory and attention (WAIS Letter Number Sequencing, Trail 
making B), verbal learning and reasoning (FAS, HVLT-R) and speed of 
processing (Trail Making A, WAIS Coding). 
We also collected Global Assessment of Functioning (GAF) scores 
(Pedersen et al., 2007), using the split version to separately score 
symptom levels and functioning. We used the AUDIT (Bush et al., 1998) 
and DUDIT (Berman et al., 2007) scales to record alcohol and drug use. 
2.7. Data analysis and statistical methods 
We used SPSS to calculate the percentage of participants with 
cognitive impairment at baseline and each follow-up. The cut-off for 
impairment was set at an overall cognitive performance t-score of t < 35, 
i.e. > 1.5 SD below the mean in line with Heaton et al. (1991). 
2.8. Cognitive change analyses 
Longitudinal mixed effect (LME) models in R were used to assess 
global cognitive change during the 12-month follow-up period. We 
chose this analysis both for its ability to handle missing data, given the 
commonly high drop-out rate in antipsychotic drug studies, and to ac-
count for dependencies in the data arising from repeated measurements 
of the same individuals. For the LME analyses, we assumed that missing 
data were missing at random. 
The first model examined global cognitive score change over time for 













0 6 26 52
Fig. 1. Change in overall cognitive performance t-scores 
over time per drug. 
Legend: 
Red – Amisulpride 
Green – Aripiprazole 
Blue - Olanzapine.   
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random intercept was included as a random effect to account for intra- 
individual correlation. We also calculated change over time in the 
three cognitive domains working memory, verbal learning and 
reasoning, and speed of processing, for the full sample and for the 
medication groups. 
Two further models, based on ITT and PP groups respectively, were 
designed to examine any differences in effects of aripiprazole, olanza-
pine and amisulpride on cognitive change over 12 months. Fixed effects 
were time and medication as well as the interaction between these. 
Amisulpride was used as a reference drug in the analyses, with a random 
intercept included like previously. 
A fourth model was designed to compare cognitive change between 
participants with schizophrenia, and those with other psychotic disor-
ders. The model was analogous to the medication analyses, with diag-
nosis entered as a fixed effect in place of medication. 
We used one-way ANOVAs to compare DDD as well as antipsychotic 
polypharmacy between the three medication groups (amisulpride, ari-
piprazole and olanzapine), for both ITT and PP analyses. We also per-
formed a post-hoc power analysis to investigate the likelihood of our 
data set discovering significant differences in cognitive performance 
assuming it was representative of population data. 
3. Results 
3.1. Participant characteristics and antipsychotic use 
Table I lists baseline demographic and clinical characteristics for 
participants (n = 104) as a whole and for the ITT groups. Ethnic minority 
individuals made up 6.7% of the sample, relatively close to the Sta-
vanger (8.8%) and Bergen (7.0%) population proportion of non- 
European ethnicities (Statistisk Sentralbyrå, 2019). There were no sig-
nificant differences between ITT groups in demographic variables. 
For the ITT groups overall, 82.7% (n = 86) accepted the #1 allocated 
drug, while 17.3% switched. The ITT group percentage to reject the #1 
drug was 12.1 (n = 4) for amisulpride, 9.4 (n = 3) for aripiprazole and 
28.2 (n = 11) for olanzapine. A Chi square test showed no significant 
differences between groups (X2 = 5.26, df = 2, p = .074) as to #1 drug 
acceptance. 
3.2. Study drug doses and polypharmacy 
For the ITT group analysis, respective mean study drug doses and 
standard deviations to Visit 2 were 250.00 (170.11) mg for amisulpride, 
12.35 (5.36) mg for aripiprazole and 10.83 (3.73) mg for olanzapine. 
Corresponding Visit 2 Defined Daily Doses (DDD) were 0.62 (0.42) for 
amisulpride; 0.82 (0.36) for aripiprazole; and 1.12 (0.41) for olanza-
pine. Table II shows dosing and DDD details for follow-ups with neu-
rocognitive testing, with mean serum levels overall and per visit 
displayed in Table III. One-way ANOVAS found no significant differ-
ences in DDD for any of these follow-ups. 
Groups did not differ in use of antipsychotics ahead of BeSt InTro 
inclusion. At baseline, 38.5% (n = 40) of participants received some 
form of additional APs. For ITT groups, the percentage receiving addi-
tional APs at baseline were 39.4 (n = 13) for amisulpride, 34.4 (n = 11) 
for aripiprazole and 41.0 (n = 16) for olanzapine. One-way ANOVAs 
showed no significant difference between ITT groups for the proportion 
receiving additional APs at baseline nor any other visit. Baseline PP 
group percentages receiving additional APs were 46.2 (n = 18) for 
amisulpride, 38.2 (n = 13) for aripiprazole, and 29.0 (n = 9) for olan-
zapine. A one-way ANOVA found significant between-group differences 
(SS = 63.80, df = 91, p = .026). Post-hoc pairwise t-tests found a Bon-
ferroni corrected significant (p = .022) difference between the olanza-
pine and amisulpride groups in terms of the percentage of participants 
receiving non-study APs at baseline. There were no further significant 
differences between PP groups for later follow-ups. ANOVAs/Fisher's 
exact tests found no significant differences in additional drugs use for 
neither ITT nor PP groups for any visit. Details on additional medication 
for ITT and PP groups at each follow-up time is displayed in Table IV. 
3.3. Overall cognitive performance and change scores 
The initial mean cognitive test performance t-score across the sample 
was 42.20, increasing to 46.39 at week 52. The participant group as a 
whole saw significant improvement in average overall t-scores for 
cognitive performance from baseline to each follow-up, i.e. at 6 (Δ2.0; p 
= .002), 26 (Δ3.4; p < .001) and 52 (Δ4.2; p < .001) weeks, with a 
respective average change per day of 0.05, 0.02 and 0.01 per day to 
Table I 
Demographic and clinical data.  
ITT group All (n =
104) 
Amisulpride 
(n = 33) 
Aripiprazole 
(n = 32) 
Olanzapine 
(n = 39) 
Age mean (SD) 31.3 
(12.2) 
32.3 (11.8) 28.2 (10.2) 31.3 (12.2) 
Female (%) 37.5 42.4 31.3 38.5 
Years of education 
(SD) 
12.5 (2.7) 13.1 (3.1) 11.7 (2.2) 12.7 (2.7) 
Clinical information     
Medication naïve 
(%) 
42.3 30.3 59.4 38.5 
Age of onset (SD) (n 
= 71) 
23.3 (8.9) 25.0 (10.2) 20.3 (6.4) 24.1 (9.1) 
PANSSa Positive 
(SD) 
20.7 (4.7) 20.6 (4.3) 20.8(5.2) 20.6 (4.7) 
PANSSa Negative 
(SD) 
17.6 (5.7) 16.7 (5.6) 17.5(5.9) 18.4 (5.6) 
PANSSa General 
(SD) 
38.2 (7.7) 38.3 (8.5) 37.1 (6.1) 39.0 (8.2) 
PANSSa Total (SD) 76.4 
(14.3) 
75.6 (14.6) 75.4 (12.5) 78.0 (15.6) 
GAFb Function (SD) 36.8 (8.2) 37.6 (7.5) 34.4 (6.7) 38.0 (9.6) 
GAFb Symptoms 
(SD) 
33.8 (5.9) 34.3 (5.5) 32.7 (5.8) 34.3 (6.5) 
Diagnoses % (n)     
F20 schizophrenia 57.7 (60) 63.6 (21) 53.1 (17) 56.4 (22) 
F21 schizotypal 1.9 (2) 3.0 (1) 0 (0) 2.6 (1) 
F22 delusional 15.4 (16) 12.1 (4) 15.6(5) 17.9 (7) 
F23 brief 10.6 (11) 12.1 (4) 9.4 (3) 10.3 (4) 
F25 schizoaffective 5.8 (6) 9.1 (3) 6.3 (2) 2.6 (1) 
F28 other 1.0 (1) 0 (0) 3.1 (1) 0 (0) 
F29 unspecified 7.7 (8) 0 (0) 12.5 (4) 10.3 (4) 
Drugs and alcohol use     
Misuse/dep. alcohol 
(%) 
5.8 3.0 9.7 5.1 
Misuse/dep. drugs 
(%) 
16.5 18.2 12.9 17.9 
Note: There were no significant between-group differences in any of the de-
mographic variables. 
a Positive and Negative Symptoms Scale. 
b Global Assessment of Functioning, split version. 
Table II 
Antipsychotic drug doses (SD) and Defined Daily Doses (DDD).  
ITT 
group 
Amisulpride Aripiprazole Olanzapine 
Week mg (SD) DDD 
(SD) 
mg (SD) DDD 
(SD) 


















































Note: Although DDD is 10 mg for olanzapine, in clinical settings the dose is often 
20 mg. 
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respective visits. This corresponds to a Cohen's d of 0.53, or a medium 
effect size. Table V shows overall cognitive test and composite scores for 
baseline and each follow-up, while Table VI shows change over time for 
ITT and PP groups. At baseline, 27.9% (n = 29) showed cognitive 
impairment, defined as scoring 1.5 SD below the population mean (t <
35). For 6, 26 and 52 week follow-ups, 23.3%, 8.3%, and 17.0% scored 
at t < 35 respectively. 
3.4. Primary outcome: cognitive change per medication group over time 
Fig. 1 shows cognitive change over time with amisulpride being 
compared to aripiprazole and olanzapine. There were no significant 
differences between ITT medication groups for the primary outcome 
measure of overall cognitive change. Overall cognitive performance t- 
scores in the model increased by 2.98 points for the amisulpride group, i. 
e. a mean improvement of 6.7% over 12 months, with corresponding 
increases of 5.00 (12.6%) for aripiprazole and 5.33 (12.2%) for olan-
zapine. Per-protocol (PP) analyses yielded similar results with no sig-
nificant between-group differences. There were no significant baseline 
cognitive performance differences between neither ITT nor PP groups. 
The post-hoc power analysis found that power for the respective vari-
ables were 70% for overall cognitive performance, 80% for verbal 
abilities, 20% for processing speed and 30% for working memory. The 
percentages indicate the stipulated chance of detecting significant dif-
ferences if assuming that our data are indeed representative of popula-
tion scores. 
3.5. Secondary outcome: cognitive change in schizophrenia vs. other 
psychotic disorders 
When comparing the 57.7% (n = 60) participants with a diagnosis of 
schizophrenia (F20) to other participants, there were no significant 
differences in cognitive impairment at baseline or cognitive change over 
time between the F20 group and the group with other psychotic 
disorders. 
4. Discussion 
This pragmatic randomized trial of atypical antipsychotics effects on 
cognitive test performance over 12 months found no significant differ-
ences between the groups receiving amisulpride, aripiprazole and 
olanzapine. This is contrary to a major meta-analysis which ranked 
Table III 
Mean study drug serum levels with standard deviations.  
Week Ami Ari Ola 
Reference 
range 




Bergen and Stavanger (Norway) 
1 436.36 (460.46) 321.93 (144.82) 77.78 (34.87) 
6 777.43 (715.14) 779.43 (661.81) 101.19 (58.01) 
26 906.50 (697.60) 740.40 (416.37) 107.13 (78.76) 
52 696.67 (531.69) 321.00 (325.19) 98.20 (42.52) 
Mean 621.87 (506.96) (n =
28) 
553.99 (378.21) 
(n = 25) 
91.95 (47.36) 
(n = 21)  
Innsbruck (Austria) 
1 91.00 (55.36) 314.00 (337.76) 64.75 (15.97) 
6 148.20 (113.58) 529.0 (− ) 88.00 (11.31) 
26 299.67 (241.91) – 54.0 (− ) 
52 211.00 (155.52) – 67.0 (− ) 
Mean 244.02 (160.17) 
(n = 6) 
216.83 (146.45) 
(n = 3) 
204.13 
(307.40) 
(n = 5) 
Note: Serum analyses are given separately for Norwegian and Austrian sites due 
to international differences in reference ranges and different laboratories per-
forming analyses. 
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olanzapine as superior to amisulpride (Désaméricq et al., 2014). How-
ever, our findings are in line with two other major AA comparison 
studies, the CATIE (Keefe et al., 2007b) and EUFEST (Davidson et al., 
2009) projects, neither of which found differential effects of AAs on 
neurocognitive functioning. 
A possible explanation for the non-significant difference between 
drug groups is that our study was underpowered to detect smaller, yet 
clinically meaningful differences in performance. A post-hoc power 
analysis indicated adequate power to detect differences in overall 
cognitive performance. However, this should be interpreted with 
caution, given that if the study was underpowered, the results of the 
post-hoc power analysis are subsequently also less reliable. 
Of 144 patients enrolled in BeSt InTro overall, only 104 completed 
neuropsychological assessment. A commonly recorded reason for non- 
testing was insufficient level of general functioning. If assuming poor 
functioning in a disproportionately large fraction of those not tested, 
relatively higher levels of functioning in the current sample might have 
created ceiling effects in either test results or cognitive change. How-
ever, the low group baseline mean indicates that this would not on its 
own explain the lack of differences. 
Despite the non-significant difference between groups, there was a 
notable trend for the aripiprazole group performing worse, especially 
during the first six weeks but also across the follow-up period. This 
appears mainly driven by weaker scores in the sub-scale for speed of 
processing. Our finding is surprising given the purported positive effect 
on cognition of aripiprazole, found to boost prefrontal DA function in 
rodent studies (Li et al., 2004). The effect of aripiprazole on attention, 
especially in previously medicated subjects, should be more closely 
examined in the future. It is also possible that despite the randomization 
procedure and no statistically significant differences between ITT 
groups, the aripiprazole group in some way differed from the other 
participants. 
It should also be noted that the BeSt InTro project, of which the 
current paper is a sub-study, was designed to differentiate between drug 
effects primarily on overall psychotic symptoms load, based partly on 
meta-analysis results indicating the superior effects of olanzapine and 
amisulpride (Leucht et al., 2013). A design based on meta-analysis of 
cognitive symptom effects might be a fruitful future avenue. Future 
avenues to identify the best drugs for cognitive symptoms should also 
include exploration of new agents with novel mechanisms of action, as 
well as non-medication avenues like cognitive remediation training. 
Participants' overall cognitive performance improved significantly 
during the 12-month follow-up period, from about one standard devia-
tion below the population mean at baseline, to a t-score of 46.39 at 12 
months. This supports earlier findings from our research group that 
cognitive functioning does improve significantly during antipsychotic 
treatment (Johnsen et al., 2013), including for non-FEP participants, 
even if some impairment still remains. It also supports our finding that 
positive cognitive change can and does happen in psychosis (Anda et al., 
2016). 
The F20 subgroup of our sample also saw significant cognitive 
improvement across the follow-up period, with no significant differ-
ences to other participants in terms of change. This is in contrast e.g. to 
Table V 
Mean cognitive t-scores for total sample.   
BL mean 
(SD) t-scores 
(n = 104) 
Wk 6 mean 
(SD) t-scores 
(n = 86) 
Wk 26 mean 
(SD) t-scores 
(n = 48) 
Wk 52 mean 
(SD) t-scores 



















42.07 (9.94) 45.51 (9.69) 46.63 (8.14)  










































a Composite of HVLT-R, FAS. 
b Composite of LNS, TMB. 
c Composite of TMA, SC. 
d DKEFS Verbal fluency. 
e Halsted Reitan Trailmaking A. 
f Halsted Reitan Trailmaking B. 
g WAIS Letter-number sequencing. 
h Hopkins verbal learning test revised. 
i DKEFS symbol coding. 
Table VI 




P Predicted Δ to 
6 weeks (SD) 
Daily 
change to 6 
wks 
P Predicted Δ 
to 26 wks 
(SD) 
Daily 
change to 26 
wks 










43.16 (1.35) N/A 2.10 (1.31)  0.005  .039a 2.59 (1.48)  0.014  .032a 2.98 (1.50)  0.008  .015a 
Aripiprazole (n 
= 32) 
39.64 (1.43) .077b 0.54 (1.57)  0.013  .342b 3.96 (1.84)  0.022  .481b 5.00 (2.19)  0.014  .378b 
Olanzapine (n 
= 39) 




42.42 (1.27) N/A 2.13 (1.24)  0.051  .032a 3.48 (1.39)  0.020  .003a 4.14 (1.39)  0.011  <.001a 
Aripiprazole (n 
= 34) 
39.88 (1.34) .173b 1.10 (1.44)  0.026  .492b 3.06 (1.68)  0.018  .818b 2.05 (2.02)  0.006  .324b 
Olanzapine (n 
= 31) 
44.39 (1.44) .307b 2.47 (1.54)  0.059  .836b 3.80 (1.69)  0.022  .860b 5.83 (1.66)  0.016  .348b  
a For the Amisulpride group, p values pertain to predicted change over time for that drug. 
b For the Aripiprazole and Olanzapine groups, p values pertain to predicted effect of time and drug, i.e. difference in effect of cognition over time as compared with 
the reference drug Amisulpride. 
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the CATIE trial, whose saw limited overall improvement in participants 
with established schizophrenia. Our F20 group represents a mix of 
recently diagnosed individuals, some medication naïve, and others with 
a longer duration of illness. It is possible that a greater amount of change 
happened in the former subgroup, as indicated by our previous study 
(Anda et al., 2019), and that cognitive recovery from an acute psychotic 
episode is more likely to happen during early psychotic episodes 
regardless of diagnosis. It might also be argued that although the 
between-group difference was about 10% away from statistical signifi-
cance, it still represents a clinically meaningful difference. 
4.1. Strengths and limitations 
A major strength of the current study is the industry-independent 
funding and a pragmatic design. The broad inclusion criteria capture 
neurocognitive variability in this patient group. The open randomiza-
tion process may have been vulnerable to systematic differences in AA 
choice between clinicians or sites, given that prior experience with study 
drugs might have unpredictably affected patient and clinician drug 
choices. However, there were no indications of differences between drug 
groups in the proportion accepting the first drug offered. Open 
randomization is also more acceptable to both patients and prescribing 
physicians than a fully blinded study, yielding a more representative 
sample and more generalizable results. 
The considerable attrition rate is unfortunately common in antipsy-
chotic drug trials. This was a main motivation for selecting a mixed ef-
fects analysis in order to handle missing data. If missing cognitive 
change data are systematically related to other variables this may 
however affect the validity of findings. a missing at random assumption 
as with LME modelling yields a more robust result despite missing data, 
as compared to a listwise method assuming missing completely at 
random. Due to consent restrictions we were unfortunately unable to re- 
contact dropped-out participants to gather further data from them to 
directly assess reasons for missingness. However, missing analyses 
supported an assumption of missing at random: Medication groups did 
not differ in attrition rates, nor was attrition related to any known 
baseline characteristics. Subjects lost to follow-up were included in the 
LME model in order to strengthen its stability, but no data were imputed 
for this group for the longitudinal part of the dataset. Due to this high 
attrition, slopes may be less certain in the latter part of the follow-up 
period. It should also be noted that a common informally reported 
reason for non-participation in neurocognitive testing was that the 
person was “too unwell” to be tested. It is thus possible that clinical 
instability may be a reason for drop-out from neurocognitive testing 
throughout the follow-up period. Our results may therefore be of limited 
generalizability to those with extremely high psychotic symptom loads. 
However, any such effect is likely to have equally affected every medi-
cation group, and should thus not detract from our main comparison 
findings. Missingness in BeSt InTro has also been thoroughly assessed 
elsewhere, with findings supporting an assumption of missing at random 
(Johnsen et al., 2020). 
The present study did not use a comprehensive test battery to assess 
cognitive change. This might have contributed to masking any differ-
ences between drugs, as suggested by EUFEST authors (Davidson et al., 
2009). However, we did test four times during the 12-month follow-up 
period, with special attention paid to the early weeks when cognitive 
recovery is most likely to happen. 
A final limitation to the current findings is that repeated-measures 
studies of cognition are vulnerable to practice effects, i.e. improved 
scores at re-test measurement points due to repeated testing. However, 
the tests we used, including HVLT-R, trail making, coding and letter- 
number sequencing were recently found resistant to such effects 
(Rodriguez-Toscano et al., 2019). Any learning effects are also likely be 
randomly distributed between medication groups and should thus not 
deter us from concluding about any between-drug differences in change 
trajectory. 
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Müller, N., Möller, H.J., 2010. Effect of aripiprazole on cognition in the treatment of 
patients with schizophrenia. Pharmacopsychiatry 43 (02), 50–57. 
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